GlobeNewswire Inc.··Molecular Partners AgMolecular Partners' MP0317 Shows Promise in Nature Cancer, Sparks CD40 Agonist Competition
Molecular Partners published positive Phase 1 data for MP0317, a CD40 agonist, in Nature Cancer, demonstrating tumor microenvironment remodeling with favorable safety in advanced cancer patients.
MOLNPhase 1 clinical trialimmunotherapy